IO NewsWire

March 14, 2011 07:30 ET

(NASDAQ: VTUS) Ready for Phase III of Inferanserin

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire.

NEW YORK, NY--(Marketwire - March 14, 2011) - Ventrus Biosciences, Inc. (NASDAQ: VTUS) a pharmaceutical company focused on developing and commercializing gastrointestinal products has been featured in "The Pink Sheet Daily."

The lead product from Ventrus is Inferanserin (VEN 309) which is being developed for the topical treatment of hemorrhoids. VEN 309 should begin Phase III trials in mid 2011.

Hemorrhoids affect more than 50% of the US population over 50 years of age. The available treatments for hemorrhoids, over the counter and medically prescribed, total approximately $350 million dollars annually in sales. 

To view the entire summary of The Pink Sheet Daily article, please visit:

Other active stocks are Pacific Biosciences of California (NASDAQ: PACB) Ardea Biosciences, Inc (NASDAQ: RDEA) Ironwood Pharmaceuticals, Inc (NASDAQ: IRWD)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information